Silo Pharma, Inc.

SILO Nasdaq CIK: 0001514183

Company Information

Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation NV
Business Address 677 N. WASHINGTON BLVD, SARASOTA, FL, 34236
Mailing Address 677 N. WASHINGTON BLVD, SARASOTA, FL, 34236
Phone (718) 400-9031
Fiscal Year End 1231
EIN 462137136

Recent SEC Filings

Form Type Date Filed Document
8-K Current report of material events April 2, 2026 View on SEC
10-K Annual financial report March 27, 2026 View on SEC
8-K Current report of material events February 23, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment February 17, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment February 13, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment February 13, 2026 View on SEC
8-K Current report of material events December 29, 2025 View on SEC
4 Insider stock transaction report December 16, 2025 View on SEC
4 Insider stock transaction report November 21, 2025 View on SEC
4 Insider stock transaction report November 20, 2025 View on SEC

Annual Reports

10-K March 27, 2026
  • Lead drug candidate SPC-15 for PTSD/Anxiety secured a faster FDA approval path.
  • Development of SP-26 ketamine implant for pain relief as an opioid alternative.
View Analysis

Material Events

8-K Financial Distress December 29, 2025
High Impact
  • Silo Pharma, Inc. received an extension from Nasdaq to regain compliance with the $1.00 minimum bid price rule.
  • The new deadline for the company to meet the listing requirement is June 22, 2026.
View Analysis

Insider Trading

BUY 1 insiders 6 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2834)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.